Henda Bouali, MD
Rheumatology · Vestal, NYNPI 1053495465
Payments from drug & device makers
Across 60 payments — averaging $114.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Johnson & Johnson$2K
- AbbVie$932
- Janssen Scientific Affairs, LLC$199
- AstraZeneca$107
- ANI Pharmaceuticals, Inc.$29
- plus $71 from 4 others
What the payments were for
- Consulting fees$2,00029%
- Speaking & faculty fees$1,80026%
- Travel & lodging$91413%
- Food & beverage$2,05730%
- Education$841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 16 | $3,385 |
| Johnson & Johnson | 7 | $2,133 |
| AbbVie | 25 | $932 |
| Janssen Scientific Affairs, LLC | 2 | $199 |
| AstraZeneca | 5 | $107 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| Radius Health, Inc. | 1 | $24 |
| Novartis | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,855 in reported general payments places this provider in the 60th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 11 | $77,004 |
| Actemra ActpenTocilizumab | 12 | $48,043 |
| Febuxostat | 12 | $4,094 |
| Hydroxychloroquine Sulfate | 95 | $2,818 |
| Mycophenolate Mofetil | 26 | $2,624 |
| Celecoxib | 32 | $1,423 |
| Prednisone | 134 | $1,378 |
| Diclofenac Sodium | 28 | $836 |
| Duloxetine Hcl | 26 | $554 |
| MethotrexateMethotrexate Sodium | 22 | $471 |
| Sulfasalazine | 18 | $446 |
| Azathioprine | 17 | $404 |
| Methotrexate SodiumMethotrexate Sodium/Pf | 17 | $228 |
| Alendronate Sodium | 23 | $200 |
| Allopurinol | 17 | $187 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Vestal
- Amit SaxenaNew York$6.7M
- Cynthia AranowManhasset$5.3M
- Richard FurieNew Hyde Park$4.3M
- Robert SpieraNew York$4.3M
- David GoddardBrooklyn$3.9M
- Laurie GlimcherNew York$3.9M
- Anca AskanaseNew York$3.5M
- Grace WrightNew York$3M
- Jose ScherNew York$2.7M
- Kostas BotsoglouCheektowaga$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.